Fill - Evidence Brief: Effectiveness of (U.S. Department of Veterans Affairs)

Department of Veterans Affairs

Health Services Research & Development Service

Evidence-based Synthesis Program

Evidence Brief: Effectiveness of

Stellate Ganglion Block for

Treatment of Posttraumatic

Stress Disorder (PTSD)

February 2017

Prepared for:

Department of Veterans Affairs

Veterans Health Administration

Quality Enhancement Research Initiative

Health Services Research & Development Service

Washington, DC 20420

Prepared by:

Evidence-based Synthesis Program (ESP)

Coordinating Center

Portland VA Health Care System

Portland, OR

Mark Helfand, MD, MPH, MS, Director

Investigators:

Kim Peterson, MS

Donald Bourne, BS

Johanna Anderson, MPH

Katherine Mackey, MD

Mark Helfand, MD, MS, MPH

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

PREFACE

The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and

accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and

policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding

for four ESP Centers, and each Center has an active University affiliation. Center Directors are

recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based

Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA

Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as

designated appropriate by QUERI/HSR&D.

The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help:

· Develop clinical policies informed by evidence;

· Implement effective services to improve patient outcomes and to support VA clinical practice

guidelines and performance measures; and

· Set the direction for future research to address gaps in clinical knowledge.

The ESP disseminates these reports throughout VA and in the published literature; some evidence

syntheses have informed the clinical guidelines of large professional organizations.

The ESP Coordinating Center (ESP CC), located in Portland, Oregon, was created in 2009 to expand the

capacity of QUERI/HSR&D and is charged with oversight of national ESP program operations, program

development and evaluation, and dissemination efforts. The ESP CC establishes standard operating

procedures for the production of evidence synthesis reports; facilitates a national topic nomination,

prioritization, and selection process; manages the research portfolio of each Center; facilitates editorial

review processes; ensures methodological consistency and quality of products; produces “rapid response

evidence briefs” at the request of VHA senior leadership; collaborates with HSR&D Center for

Information Dissemination and Education Resources (CIDER) to develop a national dissemination

strategy for all ESP products; and interfaces with stakeholders to effectively engage the program.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, ESP CC Program

Manager, at Nicole.Floyd@va.gov.

Recommended citation: Peterson K, Bourne D, Anderson J, Mackey K, Helfand M. Evidence Brief:

Effectiveness of Stellate Ganglion Block for Treatment of Posttraumatic Stress Disorder. VA ESP

Project #09-199; 2017.

This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Coordinating

Center located at the Portland VA Health Care System, Portland, OR, funded by the Department of Veterans

Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research

Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its

contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans

Affairs or the United States government. Therefore, no statement in this article should be construed as an official

position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg,

employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received

or pending, or royalties) that conflict with material presented in the report.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

TABLE OF CONTENTS

Introduction ..................................................................................................................................... 3

Purpose ......................................................................................................................................... 3

Background .................................................................................................................................. 3

Methods........................................................................................................................................... 6

Results ............................................................................................................................................. 8

Literature Flow............................................................................................................................. 8

To What Extent Does SGB Provide Clinically Relevant Benefits for PTSD? ............................ 8

What are SGBs Potential Harms? .............................................................................................. 10

Who is Most Likely to Benefit? ................................................................................................. 11

Summary and Discussion .............................................................................................................. 11

Limitations ................................................................................................................................. 11

Clinical and Research Implications ........................................................................................... 12

Conclusions ................................................................................................................................... 14

References ..................................................................................................................................... 15

FIGURES AND TABLES

Figure 1: Literature Flowchart ........................................................................................................ 8

Table 1. Mean Change from Baseline for SGB versus Sham ....................................................... 10

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

Background

The ESP Coordinating

Center (ESP CC) is

responding to a request

from Office of

Community

Engagement’s (OCE)

Center for

Compassionate

Innovation (CCI) for an

evidence brief on the

effectiveness of stellate

ganglion block (SGB)

for treatment of

posttraumatic stress

disorder (PTSD).

Findings from this

evidence brief will be

used to inform Subject

Matter Experts’

consideration of clinical

use and research and

program prioritization of

SGB for PTSD in the

VA.

Methods

To identify studies, we

searched MEDLINE®,

CINAHL, and more,

through December 2016.

We used prespecified

criteria for study

selection, data

abstraction, and rating

internal validity, and

strength of the evidence.

See our PROSPERO

protocol for our full

methods.

EXECUTIVE SUMMARY

Posttraumatic stress disorder (PTSD) is the third most common

psychiatric diagnosis among Veterans seen in the Veterans Health

Administration (VHA). PTSD can be debilitating, leading to a decline

in quality of life (QoL) and causing significant medical, mental health,

interpersonal, and social impairment. First-line treatments for PTSD

include psychotherapy, pharmacotherapy, or their combination;

however, several challenges have been identified in their effectiveness

and reach. Stellate ganglion block (SGB), also called cervical

sympathetic block, has been promoted as an adjuvant in individuals

with PTSD who have not fully responded to conventional therapies.

One proposed mechanism of action is that SGB might inhibit

connections between the peripheral sympathetic nerve system and

regions of the cerebral cortex thought to be abnormally activated in

PTSD. Some proposed benefits of SGB for PTSD include (1) it may

destigmatize treatment by offering a biologic approach to PTSD

management, (2) it may offer a fast-acting treatment alternative with

improvements reported within minutes to days of the procedure, and

(3) it may increase compliance as it does not require continuous daily

or weekly administration.

Our objectives were (1) to determine to what extent SGB provides

clinically relevant benefits for patients with PTSD, (2) to determine

SGB’s potential harms, and (3) to identify Veterans who are most

likely to benefit from SGB.

In uncontrolled, unblinded, retrospective case series, SGB for PTSD

had high rates of rapid clinical improvement in PTSD symptoms (70%

to 75%). However, findings from the first randomized trial (RCT) of

SGB for PTSD were inconclusive, neither confirming nor refuting

findings from case series. In the RCT, the range of mean percent PTSD

improvement after one round of SGB was 5.4% to 14.7%, and was

12.1% to 21.2% after the second round, which was no better than an

injection of saline. However, certain population characteristics and

intervention and comparator techniques used in the RCT were

suboptimal for determining efficacy and it was too small to estimate rates of serious

complications. The majority of study participants were active-duty military personnel with

unknown psychological and medical comorbidities and previous conventional therapy trials.

The pattern of very encouraging results in a few case series, followed by a negative RCT, is quite

common. The pattern suggests that, while it is possible that some patients benefit, the response

rates seen in case series will not hold up in actual practice. Substantial uncertainty remains about

the potential harms of SGB as well. The RCT, as well as RCTs of SGB for complex regional

pain syndrome (CRPS), were inadequately powered to support or refute findings from the

frequently cited, but methodologically weak, 1992 German questionnaire survey of 45,000 SGBs

that found 1.7 instances of severe complications per every 1000 individuals.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

Evidence was also insufficient to determine which Veterans are most likely to benefit from SGB

for PTSD. Clinical factors that could be used to select patients include failure to respond to, or

high risk of noncompliance with, conventional therapies, low risk of bleeding and other

complications, patient preference, and availability of SGB.

To determine whether some patients benefit, and which Veterans are most likely to benefit, new

RCTs designed to correct the deficiencies of the first trial should be conducted. These trials, as

well as a registry that adheres to methodological standards, should also be designed to ascertain

the frequency and severity of side effects. If further investigation of SGB for PTSD is prioritized

in VA, it should include a clear plan to address the following identified important limitations that

are also characteristic of research on conventional treatments for PTSD as a whole: (1)

adequately powering studies to measure clinically relevant benefits and harms; (2) improved

documentation of predominant PTSD symptom types, index trauma types, and comorbidities; (3)

improved documentation of prior and concomitant PTSD treatments; and (4) use of longer

follow-up periods to determine sustainability. We did not investigate whether SGB should be a

higher priority than other innovative treatments for PTSD, such as ketamine, MDMA (±3,4-

Methylenedioxymethamphetamine)-assisted psychotherapy, and cranial electrical stimulation, or

comparative costs.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

EVIDENCE BRIEF

INTRODUCTION

PURPOSE

The ESP Coordinating Center (ESP CC) is responding to a request from Office of Community

Engagement’s (OCE) Center for Compassionate Innovation (CCI) for an evidence brief on the

effectiveness of stellate ganglion block (SGB) for treatment of posttraumatic stress disorder

(PTSD). Findings from this evidence brief will be used to inform Subject Matter Experts’

consideration of clinical use and research and program prioritization for SGB for PTSD in VA.

BACKGROUND

Posttraumatic Stress Disorder (PTSD) and Its Impact

Posttraumatic stress disorder (PTSD) is a trauma- and stress-related disorder than can develop

following exposure to a traumatic event. PTSD can affect survivors not only of combat

experience, but any life-threatening event or traumatic emotional experience. According to the

Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5), PTSD is defined

by 4 clusters of symptoms: (1) intrusive re-experiencing of a traumatic event, (2) avoidance of

trauma-related stimuli, (3) negative changes in mood and cognition, and (4) persistent

physiological arousal and reactivity. Diagnosis of PTSD requires that the symptoms significantly

impair functioning and last for at least one month.

PTSD is the third most common psychiatric diagnosis among Veterans seen in the Veterans

Health Administration (VHA).

The latest reports on VHA healthcare utilization by Operation

Enduring Freedom/ Operation Iraqi Freedom/ Operation New Dawn (OEF/OIF/OND) Veterans

shows that 378,993 Veterans have been diagnosed with PTSD at some point between FY 2002

and FY 2015.

The lifetime prevalence of PTSD in Veterans (12-30%)

4-9

has consistently been

found to be greater than that observed in the general population (7%).

10,11

According to research

summarized by the Department of Veterans Affairs National Center for PTSD (NCPTSD),

experts estimate that up to 20% of Operation Enduring Freedom and Operation Iraqi Freedom

(OEF/OIF) Veterans,

4-6

up to 12% of Gulf War Veterans,

and up to 30% of Vietnam War

Veterans

8,9

have experienced PTSD. Consequently, the need for PTSD treatment may increase

within the Veteran population in the coming years.

PTSD can be debilitating and lead to a decline in quality of life (QoL).

Mental health

impairments can include increased risk of suicide, depression, other mood/anxiety disorders,

eating disorders, and substance use disorders.

14-19

PTSD has also been linked to increased rate of

aging and early mortality.

Interpersonal and social impairments can include strained marital

and family relations, parenting difficulties, and difficulty finding and maintaining

employment.

21-26

As a result, overall healthcare service needs are high among people with

PTSD.

Congressional Budget Office data from fiscal years 2004 through 2009 indicate that,

compared to Veterans without PTSD, those with PTSD were more likely to use VHA healthcare

services in general ‒ regardless of their relationship to a PTSD diagnosis.

In 2015, the RAND

Center for Military Health Policy Research reported that for OEF/OIF Veterans with PTSD, the

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

estimated 2-year costs to society – from healthcare needs and lost productivity – were

substantial.

Challenges of Conventional Treatments

Commonly recommended first-line treatments for PTSD include psychotherapy,

pharmacotherapy, or their combination.

28-33

Examples of psychotherapy modalities used for

PTSD include: Exposure-based therapies (ET), Cognitive-based therapies (CPT), Stress

Inoculation Training (SIT), and Eye Movement Desensitization and Reprocessing (EMDR).

These psychotherapies include 5 core components: (1) narration, (2) cognitive restructuring, (3)

in vivo exposure, (4) stress inoculation skills (eg, relaxation), and (5) psychoeducation.

Pharmacotherapy for PTSD typically consists of antidepressants, such as selective serotonin

reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). If

unsuccessful, treatment may expand to mood stabilizers, anticonvulsants, antipsychotics, or other

agents.

However, several challenges have been identified in the effectiveness and reach of common

psychological and pharmacological treatments for PTSD.

The overall success of current PTSD

treatments is low and variable, with rates of remission generally ranging from 30% to 40%.

35,36

Whether treatment success differs based on particular clinical characteristics is largely

unknown.

According to surveys of Veterans with PTSD, barriers to seeking and accessing

treatment include concerns about treatment, emotional readiness for treatment, stigma, and

logistical difficulties.

37,38

Contributors to poor compliance with common psychological and

pharmacological treatments may include the many weeks to months required, potential side

effects, and co-morbidities.

Due to these limitations, there is a great need for innovative

approaches to further improving the health and well-being of people with PTSD.

What is Stellate Ganglion Block (SGB)?

The stellate ganglion, part of the sympathetic nervous system, is a cluster of nerve cell bodies

located between the C6 and C7 vertebrae. Injection of local anesthetic to the stellate ganglion, a

procedure known as stellate ganglion block (SGB), inhibits sympathetic nerve impulses to the

head, neck, and upper extremities. SGB is an outpatient procedure, performed by

anesthesiologists or interventional pain management physicians, that has been used to treat

various disorders including complex regional pain syndrome, hot flashes, migraines, facial pain,

and upper extremity pain.

Because the stellate ganglion is connected to brain regions thought to be abnormally activated in

PTSD, such as the amygdala, SGB has been explored as a potential alternative treatment option

for PTSD.

Studies that have examined brain imaging before and after PTSD treatment provide

potential evidence of this biological rationale for the effect of SGB on PTSD. A 2015 study

comparing fluorodeoxyglucose (FDG) PET brain scans of 5 Veterans with combat-related PTSD

one week before and after undergoing right-sided SGB found that the right amygdala and

hippocampal areas were relatively overactive when PSTD symptoms were more prominent.

2016 longitudinal study comparing functional MRIs and symptom scores of 72 Veterans with

and without PTSD during which PTSD patients received trauma-focused therapy suggested that

higher baseline dorsal anterior cingulate cortex (dACC), insula, and amygdala activation may

predict poor response to PTSD treatment.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

SGB has also been associated with biologic markers of sedation. A 2014 study on the effects of

SGB in rats found that SGB was associated with decreased EEG activity, suggesting a sedative

effect.

Similarly, a 2015 study of healthy adult volunteers found that SGB was associated with

a sedative effect compared to sham as measured by the bispectral index system (based on EEG)

and Observer’s Assessment of Alertness/Sedation scores.

The specific mechanism of action by which SGB may mitigate PTSD symptoms remains

incompletely understood. SGB results in peripheral vasodilation, but the mechanism by which

SGB impacts symptoms of PTSD is likely more complex. A proposed explanation for the

prolonged effectiveness of SGB on PTSD, as well as symptoms of hot flashes and complex

regional pain syndrome, is that application of local anesthetic to the stellate ganglion leads to a

reduction in nerve growth factor and a resulting decrease in sympathetic nerve sprouting and

brain norepinephrine levels.

Ropivacaine or bupivacaine, 7 cc of 0.5% solution, are the most common anesthetic types and

dosages used in SGB.

To avoid potential serious adverse effects of inaccurate needle placement

to the anatomy surrounding the stellate ganglion, use of image-guidance techniques such as

ultrasound, fluoroscopy, or computed tomography are recommended to help visualize the

injection area. SGB performance also requires the availability of continuous vital sign

monitoring technology and resuscitative equipment and personnel to monitor and respond to

changes in respiration and circulation that may occur as a result of unintentional intravascular

injections. Identification of a successful SGB is made by diagnosing temporary Horner’s

syndrome occurring within 15 minutes of the procedure – a constricted pupil, weak and droopy

eyelid, decreased sweating, and potential inset eyeball – which is recommended to be

quantitatively graded by a third-party medical professional.

Regulation, Guidance, and Advocacy for SGB

Ropivacaine and bupivacaine are FDA-approved for production of local or regional anesthesia

for surgery and acute pain management, including in the head and neck area. Injection of these

drugs into the stellate ganglion for PTSD is considered an “off-label” use for a different disease

than described in the drug label, which is legal and unregulated. PTSD treatment guidelines from

the VA/DoD and other professional societies do not reference SGB,

28,29,33

but in 2015,

Lieutenant Colonel Sean W. Mulvaney, MD and colleagues published clinical guidelines in the

Journal of Special Operations Medicine.

The main source of public advocacy for SGB for

PTSD comes from pain management anesthesiologist, Eugene Lipov, MD, who founded the

Global Post-Traumatic Stress Injury Foundation (GPTSIF) to facilitate access to innovative

biological treatment for PTSD,

and who has made numerous network television appearances

and authored numerous articles about SGB for PTSD.

48-52

Advocates such as Drs. Lipov and

Mulvaney have promoted SGB for PTSD primarily based on the notably high rates of clinically

meaningful improvement (70% to 75%) in uncontrolled case series of predominantly males in

their early forties who were active-duty military with combat-related PTSD.

39,53,54

Advocates

commonly describe SGB as safe, with the most frequently cited supporting evidence coming

from a questionnaire survey with a 51% response rate that included responses from 39 West

German departments of anesthesiology, representing approximately 45,000 SGBs, that reported

low rates (1.7 per 1000) of severe complications such as convulsions.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

What Are Possible Roles for SGB for PTSD?

SGB for PTSD has typically been promoted as an adjuvant in individuals who have not fully

responded to conventional therapies.

Some proposed benefits of SGB for PTSD include (1) it

may destigmatize treatment by offering a biologic approach to PTSD management,

(2) it may

offer a faster-acting treatment alternative with improvements reported within 30 minutes to days

of the procedure,

and (3) it increases compliance as it does not require continuous daily or

weekly administration.

Objectives of this Evidence Review

Our objectives were (1) to determine to what extent SGB provides clinically relevant benefits for

patients with PTSD, (2) to determine SGBs potential harms, and (3) to identify patients who are

most likely to benefit from SGB.

METHODS

The ESP included studies that met the following criteria:

· Population: Adults with posttraumatic stress disorder (PTSD)

· Intervention: Stellate ganglion block (SGB)

· Comparator: Any

· Outcomes:

o Clinical health outcomes: Remission and % of patients achieving minimally

important difference in PTSD symptom scores (% responding). Although no

definitive guidance has been established for prioritization of instruments and

thresholds to use to best measure clinically significant improvement in PTSD

symptoms, we used these as our general guideposts: ≥ 15-point reduction on

the Clinically-Administered PTSD Scale (CAPS),

a ≥ 10-point reduction on

the PTSD Checklist (PCL)

and a ≥ 30% reduction in general

o Intermediate benefits: Change in symptom scale scores for PTSD, depression,

functional status, quality of life

· Harms: Complications including arrhythmia; hypotension; hematoma due to injury to

adjacent vascular structures; thoracic duct injury; injection of local anesthetic into the

intravascular, intrathecal, epidural space, or brachial plexus; direct spread of local

anesthetic to the recurrent laryngeal or phrenic nerves; soft tissue infection; osteitis;

and meningitis

· Timing: Any study follow-up durations

· Setting: Any

· Study design: Systematic reviews, randomized controlled trials, or concurrently

controlled cohort studies. Case series will be briefly discussed to provide frequently

cited context, but will not be formally evaluated due to their inherent weaknesses

59,60

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

To identify articles relevant to the key questions, we searched MEDLINE®, the Cochrane

Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, CINAHL,

PsychINFO, and PILOTS on 12/30/2016 and updated on 2/7/2017, using terms for stellate

ganglion block and PTSD. (See Appendix A in the supplemental materials for complete search

strategies.) We limited the search to articles involving human subjects available in the English

language. We sought additional citations through hand-searching reference lists, relevant

journals, and consultation with content experts. Study selection was based on the eligibility

criteria described above. We searched numerous other sources to identify unpublished and less-

accessible forms of data (Appendix A in supplemental materials). Titles, abstracts, and full-text

articles were reviewed by one investigator and checked by another. All disagreements were

resolved by consensus.

Four reviewers (KP, DB, JA, KM) independently assessed the internal validity of the randomized

controlled trial using criteria established by the Drug Effectiveness Review Project.

This

approach involves assigning ratings of good, fair, or poor quality to reflect the adequacy of

methods for randomization, allocation concealment, blinding, outcome measurement and

analysis, and acceptability of levels of adherence and attrition. One reviewer abstracted data

from the randomized controlled trial on its design, patient characteristics, and results for each

included outcome and these were then checked by another. All disagreements were resolved by

consensus.

We graded the strength of the evidence based on the AHRQ Methods Guide for Comparative

Effectiveness Reviews.

This approach incorporates 4 key domains: risk of bias (includes study

design and aggregate quality), consistency, directness, and precision of the evidence. It also

considers other optional domains that may be relevant for some scenarios, such as a dose-

response association, plausible confounding that would decrease the observed effect, strength of

association (magnitude of effect), and publication bias. Strength of evidence is graded for each

key outcome measure and ratings range from high to insufficient, reflecting our confidence that

the evidence reflects the true effect. Strength of evidence grades were first completed by one

reviewer and checked by another and all disagreements were resolved using consensus.

A draft version of this report was reviewed by 3 technical experts and clinical leadership. Their

comments and our responses are presented in the supplemental materials.

The complete description of our full methods can be found on the PROSPERO international

prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO/; registration

number CRD42016053908).

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

RESULTS

LITERATURE FLOW

Searches resulted in 174 potentially relevant articles after removal of duplicates (Figure 1). Of

these, we identified one study with a concurrent comparison group, which was an RCT.

Detailed reasons for exclusion are provided in Appendix B of the supplemental materials.

Figure 1: Literature Flowchart

TO WHAT EXTENT DOES SGB PROVIDE CLINICALLY RELEVANT

BENEFITS FOR PTSD?

Case Series

Uncontrolled case series of predominantly males in their early forties who were active-duty

military with combat-related PTSD (N=202) have found high rates of clinically meaningful

improvement with SGB (70% to 75%),

39,64,65

including in those with extreme PTSD.

Case

series can be valuable in providing an initial indication of promise. However, their lack of a

control group is a major drawback that prevents drawing conclusions regarding treatment

effect.

For example, it is quite common to see very encouraging results in a few case series,

followed by smaller benefits or contradictory findings in subsequent RCTs.

10 records identified through

reference lists and hand searching

155 titles and abstracts excluded

19 full-text articles assessed for eligibility

18 full-text articles excluded

(See supplementary materials for

exclude reasons)

1 comparative study included in synthesis

249 records identified through database

searching (Date: 12/2016)

89 records from Medline

27 records from CINAHL

13 records from Cochrane

22 records from PsychINFO

98 records from PILOTS

174 titles/abstracts screened for eligibility after removal of duplicates

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

Randomized Trials

To date there is only one published randomized trial on SGB for PTSD.

This study compared

ultrasound-guided SGB with 5 cc of 0.5% ropivacaine to an inactive sham procedure with

normal saline, in 42 primarily limited-duty male military participants with both combat and

noncombat PTSD.

SGB was administered on the right side of the neck, generally at the C6

level. The main finding of this RCT was that at one week and one month after the first round of

treatment, the magnitude of mean reduction in PTSD symptoms for SGB and sham neither met

the proposed criteria for clinical relevance nor were different between groups, regardless of

whether they were measured based on the Clinically-Administered PTSD Scale (CAPS) or the

PTSD Checklist (PCL) (Table 1). In the subset of patients who received a second round of SGB

or sham, the SBG group reached a clinically significant reduction after one week based on the

CAPS, but not the PCL, but again there were no significant differences between SGB and sham.

Because these findings come from a single study with imprecise findings, moderate

methodological limitations, and did not directly focus on clinically relevant outcomes or use the

most common administration techniques, they provide an insufficient basis upon which to draw

conclusions about SGB for treatment of PTSD in Veterans. Although this study did well in using

blinded outcome assessors, we rated the methodological quality of this trial as fair because there

were more active-duty participants in the SGB group (96% vs 73%), attrition was high overall

(57%) – primarily due to “lost to follow-up at 3 month post treatment or completed outside of 3

month post treatment window” – and was higher in the SGB group (67% vs 40%), and the study

did not report on or account for potential between-group differences in concurrent PTSD

treatments. Although no definitive guidance has been established for prioritization of instruments

and thresholds to use to best measure clinically significant improvement in PTSD symptoms, this

trial did not report on the key outcomes that have been suggested as general guideposts: ≥ 10- to

15-point reduction on the CAPS,

a ≥ 10-point reduction on the PCL,

and/or a ≥ 30%

reduction in general.

Although in previous case series the most commonly used anesthetic type

and dosage used have been 7 cc of ropivacaine, or bupivacaine 0.5% solution, this trial used 5 cc

ropivacaine, a 28%-lower dose, and provided no rationale for doing so. Also, it is unclear

whether the ropivacaine injection actually reached the stellate ganglion in all patients. Although

the stellate ganglion is typically located at C6 to C7, the level of target needle placement was C5

to C6 in this study. Although the study author confirmed that the injection was “typically” at C6,

some could have been at C5 and missed the stellate ganglion. Other commonly criticized

limitations of this trial that may have altered SGB effects include that (1) it used an inappropriate

population who were in the process of disability evaluation and may have had secondary

financial incentives to resist treatment,

63,67

and (2) the use of saline instead of an active control

that mimicked the side effects of SGB was potentially inadequate and may have reduced the

effectiveness of the blinding, as patients may have been able to easily tell if they received SGB

or sham based on the occurrence of the Horner’s syndrome eye droop. Effectiveness of the

blinding was not formally assessed.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

Table 1. Mean Change from Baseline for SGB versus Sham in the RCT

First Round

Second Round

One week

One month

One week

One month

Scale

SGB

Sham

SGB

Sham

SGB

Sham

SGB

Sham

CAPS

-12.7

N=27

-11.3

N=15

-6.6

N=27

-8.8

N=14

-17.8

N=18

-9

N=12

-7.8

N=14

-4.3

N=12

PCL

-3.6

N=26

-4.1

N=15

-2.0

N=27

-2.4

N=13

-7.9

N=17

-4.6

N=12

-6.5

N=12

-6.3

N=12

Abbreviations: CAPS = Clinically-Administered PTSD Scale; PCL = PTSD Checklist; SGB = Stellate Ganglion

Block

WHAT ARE SGB’S POTENTIAL HARMS?

Substantial uncertainty remains about the potential serious harms of SGB due to a lack of

adequately powered studies using clearly reliable and valid assessment methods. Although the

frequently cited 1992 West German questionnaire survey of approximately 45,000 SGBs from

39 anesthesiology departments appears to provide the most precise estimates of serious

complications, it has important methodological weaknesses that seriously limit our confidence in

its findings. At 1.7 per 1000, rates of severe complications, such as convulsions, were reportedly

low in this questionnaire survey.

However, we have no information about what methods were

used to collect and analyze these data, such as the rating criteria used, how they were

implemented, what the time period was between the procedure and outcome assessment, what

data monitoring standards were used to reduce error, the level of which and how missing data

were handled, and how consistent these factors were across departments. Without this

information, we cannot be sure of the reliability and validity of these data. Compared to the

“blind” technique used in the West German SGBs from the survey, we agree that the modern

standard of using image-guidance techniques has the potential to increase needle placement

accuracy and result in lower severe complications than reported in this survey. However, we

have no way of knowing how much or in what direction the potential limitations in the outcome

assessment methods may affect the reported rates.

Although RCTs of SGB for PTSD,

and CPRS,

and case series of SGB for PTSD,

39,54,69

may

have used stronger assessment methods, their findings are limited by imprecision and do not

importantly improve our knowledge about the risk of serious complications. In the RCT and case

series of SGB for PTSD,

there were no instances of serious complication such as arrhythmia,

hypotension, hematoma due to injury to adjacent vascular structures, thoracic duct injury,

injection of local anesthetic into the intravascular, intrathecal, or epidural space or brachial

plexus, direct spread of local anesthetic to the recurrent laryngeal or phrenic nerves, soft tissue

infection, osteitis, or meningitis. In the RCT,

after one month post-injection, 28 mild adverse

events were recorded, resulting in a potential complication rate of 33%. An IRB-designated

scientific reviewer categorized the adverse events as “Unrelated,” “Remote,” “Possible,” or

“Related.” Ten of the events were classified as “Related” or “Possible,” for a complication rate

of 12%. There was no significant difference in the rate of complications between the SGB and

sham injection groups. Complications included increased injection site pain, which could

potentially have been reduced by using a smaller needle such as in prior studies (20 gauge in

RCT vs 22-25 gauge in case series). The most notable event was prolonged eye drooping, which

was observed in one patient and resolved after 4 days.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

Because of the limited data on harms for SGB in PTSD, we looked to the larger literature on its

use for CRPS. A 2016 Cochrane review on sympathetic blockades for CRPS identified 3 studies

that provided specific data regarding adverse effects of SGB for CRPS (N=115).

Adverse event

rates ranged from 0% to 14.3% and included significant nausea and emesis, paresthesia during

needle positioning, pain at the injection site, varying rates of drowsiness, dizziness, or hoarseness

based on the anesthetic used, increased pain, headache, dysphagia, hematoma, dyspnea,

shivering, cold feeling, face swelling, mouth numbness, and blurred vision. The most prevalent

complaint was pain at the injection site. Due to the small size of the included studies, Cochrane

review authors could not draw conclusions regarding the safety of sympathetic blockades.

WHO IS MOST LIKELY TO BENEFIT?

There is insufficient information to determine which Veterans, if any, are most likely to benefit

from SGB for PTSD. We found no studies that compared outcomes between subgroups of

patients with different demographics, predominant PTSD symptom clusters, or comorbidities.

Findings from a case series of 30 active-duty military service members with combat-related

PTSD suggest that people with predominantly hyperarousal and avoidance types of symptoms

may be more likely to benefit from SGB.

Evidence for this effect is very weak as it is based on

inference from evaluation of which symptoms are most impacted after SGB, rather than from

direct comparison of response rates between people with different levels of these symptoms at

baseline.

SUMMARY AND DISCUSSION

Emergence of an intervention’s first randomized trial is always a highly anticipated event. For

SGB, however, findings from its first randomized trial for PTSD proved to be disappointing. In

uncontrolled, unblinded, retrospective case series, SGB for PTSD had high rates of rapid clinical

improvement in PTSD symptoms (70% to 75%). In the RCT, the range of mean percent PTSD

improvement after one round of SGB was 5.4% to 14.7%, and was 12.1% to 21.2% after the

second round, which was no better than an injection of saline. The RCT was too small to

estimate complication rates and did not report the number of patients in each group, if any, who

responded to treatment. Instead it reported group averages. What do we make of this? It is not

surprising that SGB’s benefits were less impressive in the RCT than in the case series, as

empirical evaluation has shown that, on average, benefits are generally larger in observational

studies.

However, what was surprising is that by using a somewhat lower than usual dose of

ropivacaine (5 cc versus 7 cc) and a population that may have been motivated to resist treatment,

design features may have limited the RCT’s chances of generating meaningful data on efficacy.

Substantial uncertainty remains about the potential harms of SGB as well, as the RCT and

previous case series in PTSD, as well as RCTs for CRPS,

were inadequately powered to

support or refute findings from the 1992 German questionnaire survey of 45,000 SGBs. We

agree with the conclusions of previous reviews that further research is needed to more precisely

determine the balance of benefits and harms of SGB for PTSD.

39,52,72

LIMITATIONS

Overall, a key limitation of the evidence on SGB is that it is based primarily on uncontrolled,

unblinded studies. Also key is that evidence on SGB for PTSD has unclear applicability to

Veterans. Although most studies have been conducted in military populations, the majority were

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

active-duty military members. In the largest case series (N = 166), a majority of participants

continued exposure to combat after treatment.

The majority of study participants were male, as

in VA, but mean age was late thirties to early forties and prevalence of depression, anxiety, pain,

and other medical comorbidities was unclear.

The limitations of the evidence base for SGB for PTSD are similar to those for other PTSD

treatments.

First, SGB studies have generally been underpowered to adequately measure the

most clinically important outcomes of remission, response, and serious adverse events. Second,

although SGB has been recommended for use as an adjuvant for other therapies,

evidence is

insufficient to support recommendations about specifically when to initiate SGB in the order of

recommended conventional pharmacotherapies and psychotherapies. How much failed

conventional therapy is “enough” before trying SGB? Although likely many study participants

had already failed “gold standard” therapy and their lack of success suggests the need for an

innovative approach, the studies’ lack of specific criteria for establishing “failure” of

conventional therapy, and/or dose and duration and order of conventional therapies makes it

difficult for readers to compare their patient with those in the studies. For example, in the largest

case series of N = 166, only 3% of patients were taking psychotropic medication before SGB and

there was no information about dose and duration and no information about any psychotherapy.

In the RCT, the only information about other mental health treatments was that 9.5% participated

since deployment, 26% during deployment, and 69% after deployment, but no details were

provided about type or duration.

Third, there was insufficient information to determine

applicability to and which Veterans, if any, are most likely to benefit from SGB for PTSD, due to

inadequate documentation of predominant PTSD symptom types, index trauma types,

comorbidities, optimization of prior dose, and duration of prior treatments. Fourth, evidence is

insufficient to fully assess the clinical relevance of the benefits of SGB for PTSD. Although the

studies consistently used the recommended tools – the CAPS and the PCL – none assessed

remission (loss of PTSD diagnosis). Although the largest case series measured proportion of

patients who were “responders” using the recommended PCL criteria of a ≥ 10-point reduction,

the RCT did not measure the proportion of patients meeting any clinically relevant threshold.

Finally, we could not assess long-term sustainability of response as follow-up was generally

limited to 3 months post-SGB.

Publication bias is the primary potential limitation of our review process. We attempted to

minimize the risk of publication bias by specifically searching for unpublished studies, and we

did not find any negative case series or previously unreported outcomes. Nonetheless, we may

have missed such data.

CLINICAL AND RESEARCH IMPLICATIONS

SGB for PTSD has been recommended for use as an adjuvant in individuals who have not fully

responded to conventional therapies.

Other practical considerations that may guide treatment

decisions include access to, contraindications for, and patient preference for SGB. Access to

SGB may require efforts to increase psychiatrists’ education about SGB and promote

development of partnerships between psychiatry and anesthesiology and pain management

specialists.

Contraindications for SGB may include a history of an anesthetic allergy, and

because of the potential risks of ocular, cardiac, and circulatory adverse events, SGB should be

avoided in individuals with coagulopathy, a recent cardiac infarction, a severe conduction block,

or glaucoma.

Finally, although those who have undergone SGB have found it highly

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

acceptable,

the invasive nature of SGB may be a barrier for some candidates to try it in the first

place.

SGB for PTSD is currently supported only by evidence from uncontrolled, unblinded case series

which was neither confirmed nor refuted by a single RCT with imprecise findings, moderate

methodological limitations, and which did not directly focus on clinically relevant outcomes. In

currently used evidence grading systems,

such evidence is considered “insufficient” for

estimating an effect. More rigorous studies are needed to more precisely determine the balance

of benefits and harms of SGB for the treatment of PTSD. Both randomized trials and

observational studies can contribute to our knowledge of SGB for PTSD. RTI International is

conducting a U.S. Army-funded randomized trial that will compare SGB to placebo in a planned

enrollment of 204 active-duty military personnel with PTSD (US Army Medical Research

Acquisition Activity, grant number W81XWH-15-2-0015).

This trial will help answer the

overarching question of whether SGB is effective, but follow-up is only 8 weeks and it is not

expected to address all of the gaps in the existing evidence.

We agree with Dr. Lipov

that the VA could be an ideal setting to perform further practice-

based research on SGB for PTSD to evaluate remission, response, and serious complication

rates, with follow-up longer than 8 weeks. An observational design could be appropriate, but it

should be incorporate precautions against bias that were lacking in prior studies. In particular,

1) Rigorous standards for registry studies should be followed (see below);

2) Assessment of preferences as part of the research protocol;

3) Inclusion of Veterans with PTSD who are offered (and either do or do not undergo)

conventional treatments, followed prior to and after consideration of SGB; and

4) Outcome assessment and data analysis should be conducted by research or quality

improvement personnel who do not have strong prior views of the effectiveness of

SGB.

In addition, future VA research on SBG should include a clear plan to address shortcomings of

previous research through use of the following rigorous standards for registry studies: (1)

sufficient sample size to assess the clinically relevant benefits and harms; (2) improved

documentation of predominant PTSD symptom types, index trauma types, and comorbidities; (3)

improved documentation of prior and concomitant PTSD treatments; and (4) longer follow-up

periods.

A controlled observational study designed in this way could provide better justification for

conducting another RCT to strengthen our certainty about the benefits. If a future RCT is

undertaken, we also suggest considering adding functional magnetic resonance imaging (fMRI)

assessment both to improve our understanding of SGB’s neural mechanisms and to help clarify

the impact of inadequate blinding. Differences in fMRI results between SGB and control group

participants could help refute an argument that clinical differences were due to knowing whether

or not they got SGB.

We did not investigate whether SGB should be a higher priority than other innovative treatments

for PTSD. Examples of other potentially rapid and innovative treatments include ketamine,

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy, and cranial electrical

stimulation. Each has their own unique set of potential harms, such as addiction and

neurotoxicity, which would have to be considered in relation to SGB’s net benefits. Cost of these

innovative treatments compared to conventional psychotherapy and pharmacotherapies should

also be assessed in the prioritization process. SGB costs have been estimated to be lower than

conventional PTSD therapies ($2,000 for two SGB injections vs a range of $6,000 to $30,000).

However, we have not formally evaluated comparative costs or how these estimates apply to the

current VA environment.

For additional related evidence review work, we recommend that a review of the state of the

science of PTSD outcome assessment methods, such as has been done in the field of chronic pain

outcome assessment,

could be useful in informing the direction of future research for PTSD as

a whole.

CONCLUSIONS

Findings from the first RCT of SGB for PTSD were inconclusive, neither confirming nor

refuting findings of rapid and high rates of clinically relevant improvement and low risk of

serious adverse events from unblinded, uncontrolled case series. It is appropriate to listen to

criticism of the RCT, envision a better study of SGB for PTSD, and investigate whether SGB

should be a higher priority than other innovative treatments for PTSD.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders

(DSM-5®). American Psychiatric Pub; 2013.

2. Stecker T, Fortney J, Owen R, McGovern MP, Williams S. Co-occurring medical,

psychiatric, and alcohol-related disorders among veterans returning from Iraq and

Afghanistan. Psychosomatics. Nov-Dec 2010;51(6):503-507.

3. Group EPP-DH. Analysis of VA Health Care Utilization among Operation Enduring

Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND)

Veterans, from 1st Qtr FY 2002 through 2nd Qtr FY 2015. In: Affairs V, ed. Washington,

DC2015.

4. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in

Iraq and Afghanistan, mental health problems and barriers to care. U.S. Army Medical

Department journal. Jul-Sep 2008:7-17.

5. Terhakopian A, Sinaii N, Engel CC, Schnurr PP, Hoge CW. Estimating population

prevalence of posttraumatic stress disorder: an example using the PTSD checklist.

Journal of traumatic stress. Jun 2008;21(3):290-300.

6. Holdeman TC. Invisible wounds of war: psychological and cognitive injuries, their

consequences, and services to assist recovery. Am Psychiatric Assoc; 2015.

7. Kang HK, Natelson BH, Mahan CM, Lee KY, Murphy FM. Post-traumatic stress

disorder and chronic fatigue syndrome-like illness among Gulf War veterans: a

population-based survey of 30,000 veterans. American journal of epidemiology. Jan 15

2003;157(2):141-148.

8. Dohrenwend BP, Turner JB, Turse NA, Adams BG, Koenen KC, Marshall R. The

psychological risks of Vietnam for U.S. veterans: a revisit with new data and methods.

Science (New York, N.Y.). Aug 18 2006;313(5789):979-982.

9. Kulka RA, Schlenger WE, Fairbank JA, et al. Trauma and the Vietnam war generation:

Report of findings from the National Vietnam Veterans Readjustment Study.

Brunner/Mazel; 1990.

10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime

prevalence and age-of-onset distributions of DSM-IV disorders in the National

Comorbidity Survey Replication. Archives of general psychiatry. Jun 2005;62(6):593-

602.

11. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I

comorbidity of full and partial posttraumatic stress disorder in the United States: results

from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions.

Journal of anxiety disorders. Apr 2011;25(3):456-465.

12. Vasterling JJ, Aslan M, Proctor SP, et al. Longitudinal Examination of Posttraumatic

Stress Disorder as a Long-Term Outcome of Iraq War Deployment. American journal of

epidemiology. Dec 01 2016;184(11):796-805.

13. Pagotto LF, Mendlowicz MV, Coutinho ES, et al. The impact of posttraumatic symptoms

and comorbid mental disorders on the health-related quality of life in treatment-seeking

PTSD patients. Comprehensive psychiatry. Apr 2015;58:68-73.

14. Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. The

Journal of clinical psychiatry. 2000;61 Suppl 5:4-12; discussion 13-14.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

15. Panagioti M, Gooding P, Tarrier N. Post-traumatic stress disorder and suicidal behavior:

A narrative review. Clinical psychology review. Aug 2009;29(6):471-482.

16. Nock MK, Hwang I, Sampson N, et al. Cross-national analysis of the associations among

mental disorders and suicidal behavior: findings from the WHO World Mental Health

Surveys. PLoS medicine. Aug 2009;6(8):e1000123.

17. Bernal M, Haro JM, Bernert S, et al. Risk factors for suicidality in Europe: results from

the ESEMED study. Journal of affective disorders. Aug 2007;101(1-3):27-34.

18. Brewerton TD. Eating disorders, trauma, and comorbidity: focus on PTSD. Eating

disorders. Jul-Sep 2007;15(4):285-304.

19. Harned MS, Najavits LM, Weiss RD. Self-harm and suicidal behavior in women with

comorbid PTSD and substance dependence. The American journal on addictions. Sep-

Oct 2006;15(5):392-395.

20. Lohr JB, Palmer BW, Eidt CA, et al. Is Post-Traumatic Stress Disorder Associated with

Premature Senescence? A Review of the Literature. The American journal of geriatric

psychiatry : official journal of the American Association for Geriatric Psychiatry. Jul

2015;23(7):709-725.

21. Taft CT, Watkins LE, Stafford J, Street AE, Monson CM. Posttraumatic stress disorder

and intimate relationship problems: a meta-analysis. Journal of consulting and clinical

psychology. Feb 2011;79(1):22-33.

22. Lambert JE, Engh R, Hasbun A, Holzer J. Impact of posttraumatic stress disorder on the

relationship quality and psychological distress of intimate partners: a meta-analytic

review. Journal of family psychology : JFP : journal of the Division of Family

Psychology of the American Psychological Association (Division 43). Oct

2012;26(5):729-737.

23. Calhoun PS, Beckham JC, Bosworth HB. Caregiver burden and psychological distress in

partners of veterans with chronic posttraumatic stress disorder. Journal of traumatic

stress. 2002;15(3):205-212.

24. Hayes J, Wakefield B, Andresen EM, et al. Identification of domains and measures for

assessment battery to examine well-being of spouses of OIF/OEF veterans with PTSD.

Journal of rehabilitation research and development. 2010;47(9):825-840.

25. Resnick SG, Rosenheck RA. Posttraumatic stress disorder and employment in veterans

participating in Veterans Health Administration Compensated Work Therapy. Journal of

rehabilitation research and development. 2008;45(3):427-435.

26. Sherman MD, Gress Smith JL, Straits-Troster K, Larsen JL, Gewirtz A. Veterans'

perceptions of the impact of PTSD on their parenting and children. Psychological

services. Nov 2016;13(4):401-410.

27. Bass E, Golding HL. The Veterans Health Administration's treatment of PTSD and

traumatic brain injury among recent combat veterans. 2012.

28. Management of Post-Traumatic Stress Working Group. VA/DoD clinical practice

guideline for management of post-traumatic stress. Washington (DC): Veterans Health

Administration, Department of Defense. 2010.

29. Association AP. Clinical Practice Guideline for the Treatment of Posttraumatic Stress

Disorder (PTSD) in Adults [Draft]2016.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

30. Forbes D, Creamer M, Phelps A, et al. Australian guidelines for the treatment of adults

with acute stress disorder and post-traumatic stress disorder. The Australian and New

Zealand journal of psychiatry. Aug 2007;41(8):637-648.

31. Health NCCfM. Post-traumatic stress disorder: management. 2005.

32. Tol WA, Barbui C, Bisson J, et al. World Health organization guidelines for management

of acute stress, PTSD, and bereavement: key challenges on the road ahead. PLoS

medicine. Dec 2014;11(12):e1001769.

33. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch (March 2009):

Practice guideline for the treatment of patients with acute stress disorder and

posttraumatic stress disorder. Focus. 2009;7(2):204-213.

34. Hoge CW. Interventions for war-related posttraumatic stress disorder: meeting veterans

where they are. Jama. Aug 03 2011;306(5):549-551.

35. Jonas DE, Cusack K, Forneris CA, et al. Psychological and Pharmacological Treatments

for Adults With Posttraumatic Stress Disorder (PTSD). Rockville MD2013.

36. Difede J, Olden M, Cukor J. Evidence-based treatment of post-traumatic stress disorder.

Annual review of medicine. 2014;65:319-332.

37. Stecker T, Shiner B, Watts BV, Jones M, Conner KR. Treatment-seeking barriers for

veterans of the Iraq and Afghanistan conflicts who screen positive for PTSD. Psychiatric

services (Washington, D.C.). Mar 01 2013;64(3):280-283.

38. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in

Iraq and Afghanistan, mental health problems, and barriers to care. The New England

journal of medicine. Jul 01 2004;351(1):13-22.

39. Navaie M, Keefe MS, Hickey AH, McLay RN, Ritchie EC, Abdi S. Use of stellate

ganglion block for refractory post-traumatic stress disorder: a review of published cases.

Journal of Anesthesia & Clinical Research. 2014;2014.

40. Lipov EG, Joshi JR, Lipov S, Sanders SE, Siroko MK. Cervical sympathetic blockade in

a patient with post-traumatic stress disorder: a case report. Annals of clinical psychiatry :

official journal of the American Academy of Clinical Psychiatrists. Oct-Dec

2008;20(4):227-228.

41. Alkire MT, Hollifield M, Khoshsar R, Nguyen L, Alley SR, Reist C. Neuroimaging

Suggests that Stellate Ganglion Block Improves Post-Traumatic Stress Disorder (PTSD)

Through an Amygdala Mediated Mechanism. The Anesthesiology Meeting2015.

42. van Rooij SJ, Kennis M, Vink M, Geuze E. Predicting Treatment Outcome in PTSD: A

Longitudinal Functional MRI Study on Trauma-Unrelated Emotional Processing.

Neuropsychopharmacology : official publication of the American College of

Neuropsychopharmacology. Mar 2016;41(4):1156-1165.

43. Jeong S, Jeon Y, Yeo J, Baek W. The effects of stellate ganglion block on the

electroencephalogram in rats. J. 2014;28(4):601-605.

44. Yeo J, Jeon Y. Effects of stellate ganglion block on sedation as assessed by bispectral

index in normal healthy volunteers. Pain physician. 2015;18:173-178.

45. Lipov EG, Joshi JR, Sanders S, Slavin KV. A unifying theory linking the prolonged

efficacy of the stellate ganglion block for the treatment of chronic regional pain

syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Medical

Hypotheses. Jun 2009;72(6):657-661.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

46. Mulvaney SW, Lynch JH, Kotwal RS. Clinical Guidelines for Stellate Ganglion Block to

Treat Anxiety Associated With Posttraumatic Stress Disorder. J Spec Oper Med.

2015;15(2):79-85.

47. Adahan HMA, J.; Abdi, S.; Ochberg, F.; Hickey, A.; Ritchie, E.C. Global Post-Traumatic

Stress Injury Foundation. 2016. Accessed January 20, 2017.

48. Lipov E. In search of an effective treatment for combat-related post-traumatic stress

disorder (PTSD): can the stellate ganglion block be the answer? Pain Practice. Jul-Aug

2010;10(4):265-266.

49. Lipov E. Successful use of stellate ganglion block and pulsed radiofrequency in the

treatment of posttraumatic stress disorder: a case report. Pain Res Treat.

2010;2010:963948.

50. Lipov E. The use of stellate ganglion block in the treatment of panic/anxiety symptoms

(including suicidal ideation), with combat-related posttraumatic stress disorder.

Posttraumatic stress disorder and related diseases in combat veterans. Cham,

Switzerland: Springer International Publishing; Switzerland; 2015:179-196.

51. Lipov E, Kelzenberg B. Sympathetic system modulation to treat post-traumatic stress

disorder (PTSD): a review of clinical evidence and neurobiology. Journal of affective

disorders. Dec 15 2012;142(1-3):1-5.

52. Lipov E, Ritchie EC. A review of the use of stellate ganglion block in the treatment of

PTSD. Current Psychiatry Reports. 2015;17(8):599-599.

53. Lipov E, Ritchie EC. A review of the use of stellate ganglion block in the treatment of

PTSD. Current Psychiatry Reports. Aug 2015;17(8):599.

54. Mulvaney SW, Lynch JH, Hickey MJ, et al. Stellate ganglion block used to treat

symptoms associated with combat-related post-traumatic stress disorder: A case series of

166 patients. Military Medicine. Oct 2014;179(10):1133-1140.

55. Wulf H, Maier C. [Complications and side effects of stellate ganglion blockade. Results

of a questionnaire survey]. Der Anaesthesist. Mar 1992;41(3):146-151.

56. Echeburua E, de Corral P, Zubizarreta I, Sarasua B. Psychological treatment of chronic

posttraumatic stress disorder in victims of sexual aggression. Behavior modification. Oct

1997;21(4):433-456.

57. Monson CM, Gradus JL, Young-Xu Y, Schnurr PP, Price JL, Schumm JA. Change in

posttraumatic stress disorder symptoms: do clinicians and patients agree? Psychological

assessment. Jun 2008;20(2):131-138.

58. McLay RN, Wood DP, Webb-Murphy JA, et al. A randomized, controlled trial of virtual

reality-graded exposure therapy for post-traumatic stress disorder in active duty service

members with combat-related post-traumatic stress disorder. Cyberpsychology, behavior

and social networking. Apr 2011;14(4):223-229.

59. Effective Practice and Organization of Care. What study designs should be included in an

EPOC review and what should they be called.

http://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/EPOC%20Study%2

0Designs%20About.pdf. Accessed February, 2017.

60. Carey TS, Boden SD. A critical guide to case series reports. Spine. 2003;28(15):1631-

1634.

61. McDonagh MS, Jonas DE, Gartlehner G, et al. Methods for the drug effectiveness review

project. BMC Med. Res. Methodol. 2012;12:140.

Evidence Brief: Stellate Ganglion Block for PTSD Evidence-based Synthesis Program

62. Berkman ND, Lohr KN, Ansari M, et al. Grading the Strength of a Body of Evidence

When Assessing Health Care Interventions for the Effective Health Care Program of the

Agency for Healthcare Research and Quality: An Update Methods Guide for

Effectiveness and Comparative Effectiveness Reviews. 2013.

63. Hanling SR, Hickey A, Lesnik I, et al. Stellate Ganglion Block for the Treatment of

Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Regional

Anesthesia & Pain Medicine. Jul-Aug 2016;41(4):494-500.

64. Mulvaney SW, Lynch JH, Hickey MJ, et al. Stellate ganglion block used to treat

symptoms associated with combat-related post-traumatic stress disorder: a case series of

166 patients. Military Medicine. Oct 2014;179(10):1133-1140.

65. Alkire MT, Hollifield M, Khoshsar R, et al. Prolonged Relief of Chronic Extreme PTSD

and Depression Symptoms in Veterans Following a Stellate Ganglion Block The

Anesthesiology annual Meeting: Long Beach VA Healthcare System, Long Beach,

California; 2014.

66. Brignardello-Petersen R, Ioannidis J, Tomlinson G, Guyatt G. Surprising results of

randomized trials. Users’ guide to the medical literature. A manual for evidence-based

clinical practice, 3rd ed. New York: McGraw-Hill. 2015.

67. Lipov E. A Randomized, Double-Blind, Placebo-Controlled Trial of Stellate Ganglion

Block in the Treatment of Post-Traumatic Stress Disorder: Scientific Poster. J Trauma

Treat S. 2015;4:2167-1222.

68. O'Connell NE, Wand BM, Gibson W, Carr DB, Birklein F, Stanton TR. Local anaesthetic

sympathetic blockade for complex regional pain syndrome. Cochrane Database of

Systematic Reviews. 2016(7).

69. McLean B. Safety and Patient Acceptability of Stellate Ganglion Blockade as a

Treatment Adjunct for Combat-Related Post-Traumatic Stress Disorder: A Quality

Assurance Initiative. Cureus. 2015;7(9):e320.

70. Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF. Effect of

Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic

Stress Disorder. Military Medicine. Sep 2016;181(9):1135-1141.

71. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars--drug

promotion in a competitive marketplace. The New England journal of medicine. Nov 17

1994;331(20):1350-1353.

72. Summers MR, Nevin RL. Stellate Ganglion Block in the Treatment of Post-traumatic

Stress Disorder: A Review of Historical and Recent Literature. Pain practice : the official

journal of World Institute of Pain. Oct 14 2016.

73. Abdi S, Zhou Y, Saini B, Nelson J. A new and easy technique to block the stellate

ganglion. Pain Physician. 2004;7(3):327-332.

74. Olmstead K, Walters B, Morgan J, Vandermaas-Peeler R. Stellate Ganglion Block for

Treatment of Posttraumatic Stress Disorder Symptoms: A Multi-Mode Study. RTI

International; 2016.

75. Lipov EG, Navaie M, Stedje-Larsen ET, et al. A novel application of stellate ganglion

block: preliminary observations for the treatment of post-traumatic stress disorder.

Military Medicine. Feb 2012;177(2):125-127.

76. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical

trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19.

Download
Save PDF to desktop

Email
Email completed PDF

Send for Signing
Email for others to sign

Print
Print document

NAME

Evidence Brief: Effectiveness of (U.S. Department of Veterans Affairs)

View Audit Log
Print With Audit Log
Duplicate Document

Fill Online, Printable, Fillable, Blank Evidence Brief: Effectiveness of (U.S. Department of Veterans Affairs) Form

Related forms

Fillable Evidence Brief: Effectiveness of (U.S. Department of Veterans Affairs)

Fill Online, Printable, Fillable, Blank Evidence Brief: Effectiveness of (U.S. Department of Veterans Affairs) Form

Related forms

First 20 documents completely FREE!